Antiphospholipid Antibodies: Predictive Value of Laboratory Tests

• References

• 1 Italian Registry of Antiphospholipid Antibodies (IR-APA). Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Haematologica 1993; 78: 313-318
• 2 Bowie EJ, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 162: 417-430
• 3 Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce de Leon S. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a review of 500 consecutive cases. Medicine 1989; 68: 353-365
• 4 Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-488
• 5 Koike T, Matsuura E. Anti-ß2-glycoprotein I antibody: specificity and clinical significance. Lupus 1996; 5: 378-380
• 6 Kandiah DA, Sheng YH, Krilis SA. ß2-glycoprotein I: target antigen for autoantibodies in the ‘antiphospholipid syndrome’. Lupus 1996; 5: 381-385
• 7 Galli M. Non ß2-glycoprotein I cofactors for antiphospholipid antibodies. Lupus 1996; 5: 388-392
• 8 Triplett DA. Lupus anticoagulants/antiphospholipid-protein antibodies: the great imposters. Lupus 1996; 5: 431-435
• 9 Barbui T, Finazzi G. Clinical trials on Antiphospholipid Syndrome: what is done and what is needed?. Lupus 1994; 3: 303-308
• 10 Horbach DA, v.Oort E, Donders RCJM, Derksen RHWM, de GrootPG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemostas 1996; 76: 916-924
• 11 Long AA, Ginsberg JS, Brill-Edwards P, Jonhston M, Turner C, Denburg JA, Bensen WG, Cividino A, Andrew M, Hirsh J. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemostas 1991; 66: 520-525
• 12 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691
• 13 Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S, Scarano L, Girolami B, Benedetti L, Girolami A. Deep venous thrombosis and lupus anticoagulant. A case-con-trol study. Thromb Haemostas 1996; 76: 187-189
• 14 Bongard O, Reber G, Bounameaux H, deMoerloose P. Anticardiolipin in acute venous thromboembolism. Thromb Haemostas 1992; 67: 724
• 15 The Antiphospholipid Antibodies in Stroke Study Group (APASS). Clinical, radiological and pathological aspects of cerebrevascular disease associated with antiphospholipid antibodies. Stroke 1993; 24 I I-120-I-123
• 16 Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 0997-1002
• 17 Vaarala O, Mänttäri M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palouso T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-27
• 18 Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palouso T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609
• 19 Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemostas 1996; 75: 456-459
• 20 Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D’Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-536
• 21 Vianna JL, Khamashta MA, Ordi-Ros FontJ, Cervera R, Lopez-Soto A, Tolosa C, Franz J, Selva A, Ingelmo M, Vilardell M, Hughes GRV. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9
• 22 Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995; 99: 624-628
• 23 Levine SR, Brey RL, Joseph CML. Havstad S on behalf of the APASS. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992; 23 (suppl 01) 01 29-32
• 24 Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticadiolipin antibodies in young adults with cerebral ischemia. Stroke 1992; 23: 189-193
• 25 Hamsten A, Bjorkholm M, Norberg R, deFaire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular event. Lancet 1986; i 113-116
• 26 Sletness KE, Smith P, Abedlnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies and myocardial infarction and their relation to mortality, reinfarction and non-haemorrhagic stroke. Lancet 1992; 339: 451-453
• 27 Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism and intensity of warfarin anticoagulation. Thromb Haemostas 1996; 75: 859-868
• 28 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell’s viper venom time distinguish between prothrombin-dependent and ß2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-623